Hims CEO Reports $33 Million Sale of Company Stock
Hims & Hers Health Inc.’s CEO, Andrew Dudum, sold over $33 million worth of company stock in the largest insider transaction since the company's IPO four years ago.
🔥📉⚡ The Inflection That Defines $HIMS: Defend $44.50 or Collapse to $39.30? Analyst Spread: $28–$85 ⚡📉🔥
$Hims & Hers Health Inc.(HIMS)$$Teladoc Health Inc.(TDOC)$$LifeMD Inc.(LFMD)$ 🧭 Price Action at a Critical Fibonacci Zone I’m fully convinced $HIMS is at one of its sharpest turning points since listing. The stock is back in the $43s, down 11 percent in the past week, 38 percent in three weeks, and 30 percent in three months. This brutal sell-off has brought the price into the 0.90 Fibonacci retracement zone. I’m convinced this isn’t about momentum anymore, it’s about survival of structure and narrative. If $44.50 holds, bulls can stage a reversal. If it fails, the $39.30 zone becomes the likely next target. 📊 Demand Zone at $41–$42 in Focus I’m watching th
🔥📉⚡ The Inflection That Defines $HIMS: Defend $44.50 or Collapse to $39.30? Analyst Spread: $28–$85 ⚡📉🔥
$Hims & Hers Health Inc.(HIMS)$$Teladoc Health Inc.(TDOC)$$LifeMD Inc.(LFMD)$ 🧭 Price Action at a Critical Fibonacci Zone I’m fully convinced $HIMS is at one of its sharpest turning points since listing. The stock is back in the $43s, down 11 percent in the past week, 38 percent in three weeks, and 30 percent in three months. This brutal sell-off has brought the price into the 0.90 Fibonacci retracement zone. I’m convinced this isn’t about momentum anymore, it’s about survival of structure and narrative. If $44.50 holds, bulls can stage a reversal. If it fails, the $39.30 zone becomes the likely next target. 📊 Demand Zone at $41–$42 in Focus I’m watching th